558
Participants
Start Date
October 10, 2016
Primary Completion Date
April 16, 2018
Study Completion Date
August 13, 2018
ABP 710
Administered by intravenous infusion
Infliximab
Administered by intravenous infusion
Research Site, Sofia
Research Site, Fitzroy
Research Site, Plovdiv
Research Site, Plovdiv
Research Site, Woodville
Research Site, Gyula
Research Site, Pleven
Research Site, Szentes
Research Site, Veszprém
Research Site, Sliven
Research Site, Varna
Research Site, Győr
Research Site, Bad Doberan
Research Site, Hamburg
Research Site, Madrid
Research Site, Charlotte
Research Site, Hildesheim
Research Site, Orlando
Research Site, Vero Beach
Research Site, Miami Lakes
Research Site, Aventura
Research Site, Sarasota
Research Site, Tuscaloosa
Research Site, Huntsville
Research Site, Memphis
Research Site, Magdeburg
Research Site, Flowood
Research Site, Lexington
Research Site, Seville
Research Site, Grand Blanc
Research Site, St Louis
Research Site, Omaha
Research Site, Plano
Research Site, Dallas
Research Site, League City
Research Site, Peoria
Research Site, Van Nuys
Research Site, Covina
Research Site, Upland
Research Site, Hemet
Research Site, Voorhees Township
Research Site, Charleston
Research Site, Carrollton
Research Site, Houston
Research Site, Victoria
Research Site, Saint Johns
Research Site, Brno
Research Site, Hlučín
Research Site, Prague
Research Site, Prague
Research Site, Liberec
Research Site, Ostrava
Research Site, Zlín
Research Site, Pardubice
Research Site, Poznan
Research Site, Poznan
Research Site, Poznan
Research Site, Poznan
Research Site, Poznan
Research Site, Bydgoszcz
Research Site, Torun
Research Site, Krakow
Research Site, Wroclaw
Research Site, Lublin
Research Site, Warsaw
Research Site, Warsaw
Research Site, Stalowa Wola
Research Site, Bialystok
Research Site, Gdansk
Research Site, Katowice
Research Site, Elblag
Research Site, Lodz
Research Site, Barcelona
Lead Sponsor
Amgen
INDUSTRY